Live Breaking News & Updates on கீந் நல்ல மனிதன்

Stay updated with breaking news from கீந் நல்ல மனிதன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

What Are You Like? Writer Mary Beth Keane


℘℘℘
Mary Beth Keane’s novel,
Ask Again, Yes, published in May 2019, is a lyrical, moving tale spanning 40 years, about Irish American cops, family, love, alcoholism and mental illness. Told with tenderness and empathy for the human condition, it is sprinkled with just the right amount of humor to carry the story along.
NPR’s Maureen Corrigan called
Ask Again, Yes, “one of the most unpretentiously profound books I’ve read in a long time.”
Mary Beth, who took time out from promoting her book to answer our What Are You Like? questions, is the daughter of Irish immigrants. Her mother is from Mayo and her father is from Connemara – and her insights into the nature of the Irish informs her books. ....

New York , United States , Pearl River , Typhoid Mary , Mary Mallon , Johns Guggenheim , Maria Pandolfo Manchester , Maureen Corrigan , Mary Beth , Donal Ryan , Mary Beth Keane , Patricia Harty , Photo Bank , Beth Keane , Lask Again , Irish American , What Are You , Walking People , Quiet Sea , Bleecker Street , Tonight Show Starring Jimmy Fallon , Tonight Show , Jimmy Fallon , Are You , Writer Mary Beth , Irish America Magazine ,

More Support for Gene Assay to Guide Breast Cancer Treatment


email article
Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed.
The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 99.7%. Freedom from distant metastasis at 8 years was 97.6% in patients who were clinically and genomically low-risk versus 95.0% for those who were clinically high-risk but genomically low-risk.
In patients with an ultralow-risk genomic assessment, the 8-year distant metastasis-free interval (DMFI) rate was 97.8% with no adjuvant systemic therapy. That compared with an 8-year DMFI of 97.4% in patients who received only adjuvant endocrine therapy and 94.9% in patients who received ....

United States , Noord Holland , Priya Rastogi , Charles Bankhead , Josephine Lopes Cardozo , National Surgical Adjuvant Breast , American Society Of Clinical Oncology , University Of Pittsburgh , Netherlands Cancer Institute , American Society , Clinical Oncology , Surgical Adjuvant Breast , Bowel Project , Medpage Today , Endocrine Therapy , Breast Cancer , ஒன்றுபட்டது மாநிலங்களில் , நூற்த் ஹாலண்ட் , பிரியா ரஸ்டோகி , சார்லஸ் வங்கித் தலை , ஜோசபின் லோப்ஸ் கார்டோசோ , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் , நெதர்லாந்து புற்றுநோய் நிறுவனம் , அமெரிக்கன் சமூகம் , மருத்துவ புற்றுநோயியல் ,